Alpha Cognition Inc
ACOG
Rank in Stocks
#20186
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Share Price
$8.47
Last synced: 2026-10-19
Market Cap
$131.47M
Change (1 day)
3.36%
Change (1 year)
68.29%
Country
US
Trade Alpha Cognition Inc (ACOG)
Category
Healthcare
Stock split history for Alpha Cognition Inc (ACOG)
Alpha Cognition Inc stock (symbol: ACOG) underwent a total of 1 stock splits.
The most recent stock split occurred on Nov 05, 2024.
One ACOG share bought prior to Nov 05, 2024 would equal to 0.04 ACOG shares today.
The most recent stock split occurred on Nov 05, 2024.
One ACOG share bought prior to Nov 05, 2024 would equal to 0.04 ACOG shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2024-11-05 | 1:25 | x0.04 | x0.04 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
